Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Inflammatory Diseases in Brazil

Shots:

• Amgen reports the launch and commercialization of Amgevita, a biosimilar of adalimumab, available in Brazil
• The ANVISA’s approval is based on the clinical study demonstrating bio-similarity with the reference biological product, via in vitro analyzes, PK & clinical information in patients with moderate to severe psoriasis and RA
• Amgevita is a fully human IgG1 mAb targeting TNFα, a cytokine which mediates the inflammatory response and has received ANVISA’s approval for RA, PsO, CD, UC, axSpA, HS in Apr’2019

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Behance